TrialFrontiers in immunology2025

Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study.

Hang Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.